Dacomitinib (hydrate)
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) [1].
Product Specifications
CAS Number
1042385-75-0
Product Name Alternative
PF-00299804 (hydrate) ; PF-299804 (hydrate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dacomitinib-hydrate.html
Purity
99.54
Solubility
DMF : 10 mg/mL (ultrasonic)
Smiles
O=C(/C=C/CN1CCCCC1)NC2=CC3=C(C=C2OC)N=CN=C3NC4=CC=C(C(Cl)=C4)F.O
Molecular Formula
C24H27ClFN5O3
Molecular Weight
487.95
Precautions
H302, H315, H319, H335
References & Citations
[1]Lau SCM, et al. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs. 2019 Jun;79 (8) :823-831.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
beta Defensin 3 (DEFB103B) Human Gene Knockout Kit (CRISPR)
